Brief: Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models
06/05/2025 12:31
May 6 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O: GALMED ANNOUNCES FIRST TIME RESULTS IN ONCOLOGY STUDIES: ARAMCHOL SIGNIFICANTLY ENHANCES BAYER'S REGORAFENIB EFFECT IN GI CANCER MODELS GALMED PHARMACEUTICALS LTD - ARAMCHOL AND REGORAFENIB COMBINATION REDUCES TUMOR GROWTH IN MICE GALMED PHARMACEUTICALS LTD - PHASE 1B STUDY OF ARAMCHOL AND REGORAFENIB TO START Q4 2025 Source text: ID:nPn4b7Hxka Further company coverage: GLMD.O ((Reuters.Briefs@thomsonreuters.com;))